Guiot, J., André, B., Potjewijd, J., JACQUERIE, P., Cremers, S., Henket, M., Idoufkir, L., Remacle, C., Tobal, R., GILTAY, L., Moermans, C., GESTER, F., Polese, B., Hamaïdia, M., Struman, I., Louis, E., Malaise, M., de Seny, D., van Paassen, P., ... Njock, M.-S. (2025). Association of fibrotic-related extracellular vesicle microRNAs with lung involvement in systemic sclerosis. European Respiratory Journal, 2400276. doi:10.1183/13993003.00276-2024 |
Dinh Duy Thanh, Bich-Ngoc, N., Paques, C., Christian, A., Herkenne, S., Struman, I., & Muller, M. (05 December 2024). The food dye Tartrazine disrupts vascular formation both in zebrafish larvae and in human primary endothelial cells. Scientific Reports, 14 (1), 30367. doi:10.1038/s41598-024-82076-5 |
Coart, E., hara EPISKOPOU, V. L. D. D., & Struman, I. (12 September 2024). Study of the role of microRNAs-encapsulated in extracellular vesicles in osteosarcoma [Poster presentation]. BESEV (Belgium society of extracellular vesicles) annual meeting 2024, sart-tilman, Belgium. |
Shaker, B. T., Ismail, A. A., Salih, R., Hadj Kacem, H., Rahmani, M., Struman, I., & Bajou, K. (17 May 2023). The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis. International Journal of Molecular Sciences, 24 (10), 8877. doi:10.3390/ijms24108877 |
Guiot, J., Henket, M., Remacle, C., Cambier, M., Struman, I., Winandy, M.-L., Moermans, C., Louis, E., Malaise, M., Ribbens, C., Louis, R., & Njock, M.-S. (15 April 2023). Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis. Respiratory Research, 24 (1), 112. doi:10.1186/s12931-023-02413-6 |
NJOCK, M.-S.* , O'Grady, T.* , Nivelles, O., Lion, M., Jacques, S., Cambier, M., Herkenne, S., Muller, F., Christian, A., REMACLE, C., GUIOT, J., Rahmouni, S., Dequiedt, F.* , & Struman, I.*. (June 2022). Endothelial extracellular vesicles promote tumour growth by tumour-associated macrophage reprogramming. Journal of Extracellular Vesicles, 11 (6), 12228. doi:10.1002/jev2.12228 * These authors have contributed equally to this work. |
O'Grady, T.* , NJOCK, M.-S.* , Lion, M., Bruyr, J., Mariavelle, E., Galvan, B., Boeckx, A., Struman, I.* , & Dequiedt, F.*. (24 March 2022). Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels. BMC Biology, 20 (1), 72. doi:10.1186/s12915-022-01277-4 * These authors have contributed equally to this work. |
Zamberlan, M.* , Boeckx, A.* , Muller, F., Vinelli, F., Ek, O., Vianello, C., Coart, E., Shibata, K., Christian, A., Grespi, F., Giacomello, M., Struman, I., Scorrano, L.* , & Herkenne, S.*. (12 March 2022). Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth. Journal of Experimental and Clinical Cancer Research, 41 (1), 95. doi:10.1186/s13046-022-02304-6 * These authors have contributed equally to this work. |
Bhardwaj, A., Josse, C., VAN DAELE, D., Poulet, C., Chavez, M., Struman, I., & Van Steen, K. (2022). Deeper insights into long-term survival heterogeneity of Pancreatic Ductal Adenocarcinoma (PDAC) patients using integrative individual-and group-level transcriptome network analyses. Scientific Reports, 12 (11027). doi:10.1038/s41598-022-14592-1 |
Cambier, M., Henket, M., Frix, A.-N., Gofflot, S., THYS, M., Tomasetti, S., Peired, A., Struman, I., Rousseau, A.-F., Misset, B., Darcis, G., Moutschen, M., Louis, R., Njock, M.-S., Cavalier, E., & Guiot, J. (2022). Increased KL-6 levels in moderate to severe COVID-19 infection. PLoS ONE, 17 (11), 0273107. doi:10.1371/journal.pone.0273107 |
Fontaine, M., Herkenne, S., Ek, O., Paquot, A., Boeckx, A., Paques, C., Nivelles, O., Thiry, M., & Struman, I. (2022). Extracellular Vesicles Mediate Communication between Endothelial and Vascular Smooth Muscle Cells. International Journal of Molecular Sciences, 23 (1). doi:10.3390/ijms23010331 |
Guiot, J., HENKET, M., NJOCK, M.-S., MOERMANS, C., Struman, I., Corhay, J.-L., & Louis, R. (2021). La fibrose pulmonaire : des biomarqueurs à de nouveaux horizons thérapeutiques. Revue Médicale de Liège, 76 (3), 166-172. |
Parzibut, G., Henket, M., Moermans, C., Struman, I., Louis, E., Malaise, M., Louis, R., Misset, B., NJOCK, M.-S.* , & Guiot, J.*. (2021). A Blood Exosomal miRNA Signature in Acute Respiratory Distress Syndrome. Frontiers in Molecular Biosciences, 8, 640042. doi:10.3389/fmolb.2021.640042 * These authors have contributed equally to this work. |
Roblain, Q., Louis, T., Yip, C., Baudin, L., Struman, I., Caolo, V., LAMBERT, V., Lecomte, J.* , Noël, A.* , & Heymans, S.*. (2021). Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging, 13. doi:10.18632/aging.203035 * These authors have contributed equally to this work. |
GUIOT, J., Cambier, M., Boeckx, A., HENKET, M., Nivelles, O., GESTER, F., LOUIS, E., MALAISE, M., Dequiedt, F., LOUIS, R., Struman, I.* , & NJOCK, M.-S.*. (05 August 2020). Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax, 75 (10), 870-881. doi:10.1136/thoraxjnl-2019-214077 * These authors have contributed equally to this work. |
Pérez-Boza, J., Boeckx, A., Lion, M., Dequiedt, F., & Struman, I. (2020). hnRNPA2B1 inhibits the exosomal export of miR‑503 in endothelial cells. Cellular and Molecular Life Sciences. doi:10.1007/s00018-019-03425-6 |
Francart, M.-E.* , Vanwynsberghe, A.* , Lambert, J., Bourcy, M., Genna, A., Ancel, J., Perez-Boza, J., Noël, A., Birembaut, P., Struman, I., Polette, M., & Gilles, C. (2020). Vimentin prevents a miR-dependent negative regulation of tissue factor mRNA during epithelial-mesenchymal transitions and facilitates early metastasis. Oncogene, 18, 3680-3692. doi:10.1038/s41388-020-1244-1 * These authors have contributed equally to this work. |
Boeckx, A., Gourzonès, C., & Struman, I. (06 September 2019). The exosomal microRNA miR-503: a key modulator of resistance to chemotherapy in breast cancer cells [Poster presentation]. EDT-CANCEROLOGY ANNUAL MEETING 2019 RECENT BREAKTHROUGHS IN ANTICANCER DRUG RESISTANCE. |
BONHOMME, O., ANDRE, B., GESTER, F., DE SENY, D., MOERMANS, C., Struman, I., Louis, R., MALAISE, M., & GUIOT, J. (2019). Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology. doi:10.1093/rheumatology/kez230 |
GUIOT, J., Struman, I., Louis, E., Louis, R., Malaise, M., & Njock, M.-S. (2019). Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets. Journal of Clinical Medicine, 8 (9). doi:10.3390/jcm8091345 |
Durré, T., Morfoisse, F., ERPICUM, C., Ebroin, M., Blacher, S., García Caballero, M., Deroanne, C., Louis, T., BALSAT, C., Van De Velde, M., Kaijalainen, S., Kridelka, F., Engelholm, L., Struman, I., Alitalo, K., Behrendt, N., Paupert, J., & Noël, A. (2018). uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis. Nature Communications, 9 (1), 5178. doi:10.1038/s41467-018-07514-1 |
Njock, M.-S., GUIOT, J., HENKET, M., Nivelles, O., Thiry, M., Dequiedt, F., Corhay, J.-L., Louis, R., & Struman, I. (2018). Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis. Thorax. doi:10.1136/thoraxjnl-2018-211897 |
Pérez Boza, J., Lion, M., & Struman, I. (2018). Exploring the RNA landscape of endothelial exosomes. RNA. doi:10.1261/rna.064352.117 |
GUIOT, J., Struman, I., CHAVEZ, V., HENKET, M., Herzog, M., Scoubeau, K., Hardat, N., Bondue, B., Corhay, J.-L., MOERMANS, C., & Louis, R. (15 August 2017). Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clinical Epigenetics, 9, 84. doi:10.1186/s13148-017-0383-x |
Njock, M.-S., O'Grady, T., Dequiedt, F., & Struman, I. (2017). Tumour microenvironment affects the composition of endothelial cell-derived extracellular vesicles: impact in tumour progression. Journal of Extracellular Vesicles. doi:10.1080/20013078.2017.1310414 |
Blomme, A., Fahmy, K., Peulen, O., Costanza, B., Fontaine, M., Struman, I., Baiwir, D., De Pauw, E., Thiry, M., Bellahcene, A., Castronovo, V.* , & Turtoi, A.*. (2016). Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes. Oncotarget. doi:10.18632/oncotarget.13276 * These authors have contributed equally to this work. |
Rambout, X., Detiffe, C., Bruyr, J., Mariavelle, E., Cherkaoui, M., Brohee, S., Demoitie, P., Lebrun, M., Soin, R., Lesage, B., Guedri, K., Beullens, M., Bollen, M., Farazi, T. A., Kettmann, R., Struman, I., Hill, D. E., Vidal, M., Kruys, V., ... Dequiedt, F. (2016). The transcription factor ERG recruits CCR4-NOT to control mRNA decay and mitotic progression. Nature Structural and Molecular Biology. doi:10.1038/nsmb.3243 |
Freres, P.* , Wenric, S.* , BOUKERROUCHA, M., Fasquelle, C., Thiry, J., Bovy, N., Struman, I., Geurts, P., COLLIGNON, J., SCHROEDER, H., KRIDELKA, F., LIFRANGE, E., Jossa, V., Bours, V.* , Josse, C.* , & JERUSALEM, G.*. (2015). Circulating microRNA-based screening tool for breast cancer. Oncotarget. doi:10.18632/oncotarget.6786 * These authors have contributed equally to this work. |
Bovy, N., Blomme, B., Freres, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J., Noël, A., Thiry, M., Jerusalem, G., Josse, C., Bours, V., Tabruyn, S., & Struman, I. (2015). Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget. doi:10.18632/oncotarget.3520 |
Herkenne, S., Paques, C., Nivelles, O., Lion, M., BAJOU, K., Pollenus, T., Fontaine, M., Carmeliet, P., Martial, J., Nguyen, N.-Q.-N., & Struman, I. (2015). The interaction of uPAR with VEGFR2 promotes VEGF-induced angiogenesis. Science Signaling, 8 (403), 117. doi:10.1126/scisignal.aaa2403 |
Valencia, K., Luis-Ravelo, D., Bovy, N., Anton, I., Martinez-Canarias, S., Zandueta, C., Ormazabal, C., Struman, I., Tabruyn, S., Rebmann, V., De Las Rivas, J., Guruceaga, E., Bandres, E., & Lecanda, F. (2014). miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Molecular Oncology, 8 (3), 689-703. doi:10.1016/j.molonc.2014.01.012 |
Halkein, J., Tabruyn, S. P., Ricke-Hoch, M., Haghikia, A., Nguyen, N.-Q.-N., Scherr, M., Castermans, K., Malvaux, L., Lambert, V., Thiry, M., Sliwa, K., Noël, A., Martial, J., Hilfiker-Kleiner, D., & Struman, I. (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation, 123 (5), 2143-54. doi:10.1172/JCI64365 |
LAMBERT, V., Lecomte, J., Hansen, S., Blacher, S., Alvarez Gonzalez, M.-L., Struman, I., Sounni, N. E., Rozet, E., De Tullio, P., Foidart, J.-M., Rakic, J.-M., & Noël, A. (2013). Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. Nature Protocols, 8 (11), 2197-2211. doi:10.1038/nprot.2013.135 |
Tabruyn, S. P., Hansen, S., Ojeda-Fernandez, M.-L., Bovy, N., Zarrabeitia, R., Recio-Poveda, L., Bernabeu, C., Martial, J., Botella, L.-M., & Struman, I. (2013). MiR-205 is downregulated in hereditary hemorrhagic telangiectasia and impairs TGF-beta signaling pathways in endothelial cells. Angiogenesis. doi:10.1007/s10456-013-9362-9 |
Hilfiker-Kleiner, D., Struman, I., Hoch, M., Podewski, E., & Sliwa, K. (2012). 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Current Heart Failure Reports, 9 (3), 174-82. doi:10.1007/s11897-012-0095-7 |
Soares, A. R., Reverendo, M., Pereira, P. M., Nivelles, O., Pendeville, H., Bezerra, A. R., Moura, G. R., Struman, I., & Santos, M. A. S. (2012). Dre-miR-2188 Targets Nrp2a and Mediates Proper Intersegmental Vessel Development in Zebrafish Embryos. PLoS ONE, 7 (6), 39417. doi:10.1371/journal.pone.0039417 |
Nguyen, N.-Q.-N., Castermans, K., Berndt, S., Herkenne, S., Tabruyn, S., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (07 November 2011). The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation. PLoS ONE, 6 (11), 27318-27318. doi:10.1371/journal.pone.0027318 |
COLLIGNON, J., Struman, I., Tabruyn, S., Josse, C., Boukerroucha, M., JERUSALEM, G., & BOURS, V. (2011). Aspects moléculaires du cancer du sein triple négatif et les implications thérapeutiques. Revue Médicale de Liège, 66 (5-6), 393-396. |
Kinet, V., Castermans, K., Herkenne, S., Maillard, C., Blacher, S., Lion, M., Noël, A., Martial, J., & Struman, I. (2011). The Angiostatic Protein 16K Human Prolactin Significantly Prevents Tumor-Induced Lymphangiogenesis by Affecting Lymphatic Endothelial Cells. Endocrinology. doi:10.1210/en.2011-1081 |
Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., LAMBERT, V., Alvarez Gonzalez, M.-L., Colige, A., Rakic, J.-M., Noël, A., Martial, J., & Struman, I. (2011). MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS ONE, 6 (2), 16979. doi:10.1371/journal.pone.0016979 |
Sabatel, C., Cornet, A., Tabruyn, S., Malvaux, L., Castermans, K., Martial, J., & Struman, I. (2010). Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis. Molecular Cancer, 9 (1), 231. doi:10.1186/1476-4598-9-231 |
Sliwa, K., Blauwet, L., Tibazarwa, K., Libhaber, E., Smedema, J.-P., Becker, A., McMurray, J., Yamac, H., Labidi, S., Struman, I., & Hilfiker-Kleiner, D. (2010). Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121 (13), 1465-73. doi:10.1161/CIRCULATIONAHA.109.901496 |
Tabruyn, S., Memet, S., Ave, P., Verhaeghe, C., Mayo, K. H., Struman, I., Martial, J., & Griffioen, A. W. (2009). NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Molecular Cancer Therapeutics, 8 (9), 2645-54. doi:10.1158/1535-7163.MCT-09-0383 |
Nguyen, N.-Q.-N., Cornet, A., Blacher, S., Tabruyn, S., Foidart, J.-M., Noël, A., Martial, J., & Struman, I. (December 2007). Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Molecular Therapy, 15 (12), 2094-2100. doi:10.1038/sj.mt.6300294 |
Erdmann, S., Ricken, A., Merkwitz, C., Struman, I., Castino, R., Hummitzsch, K., Gaunitz, F., Isidoro, C., Martial, J., & Spanel-Borowski, K. (November 2007). The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle. American Journal of Physiology - Endocrinology and Metabolism, 293 (5), 1365-E1377. doi:10.1152/ajpendo.00280.2007 |
Nguyen, N.-Q.-N., Tabruyn, S., Lins, L., Lion, M., Cornet, A., Lair, F., Rentier-Delrue, F., Brasseur, R., Martial, J., & Struman, I. (2006). Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103 (39), 14319-14324. doi:10.1073/pnas.0606638103 |
Piwnica, D., Touraine, P., Struman, I., Tabruyn, S., Bolbach, G., Clapp, C., Martial, J., Kelly, P. A., & Goffin, V. (October 2004). Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance. Molecular Endocrinology, 18 (10), 2522-2542. doi:10.1210/me.2004-0200 |
Pan, H., Nguyen, N.-Q.-N., Yoshida, H., Bentzien, F., Shaw, L. C., Rentier-Delrue, F., Martial, J., Weiner, R., Struman, I., & Grant, M. B. (July 2004). Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Investigative Ophthalmology and Visual Science, 45 (7), 2413-2419. doi:10.1167/iovs.03-1001 |
Bentzien, F., Struman, I., Martini, J. F., Martial, J., & Weiner, R. (2001). Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Research, 61 (19), 7356-62. |
Martini, J. F., Piot, C., Humeau, L. M., Struman, I., Martial, J., & Weiner, R. I. (2000). The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Molecular Endocrinology, 14 (10), 1536-49. doi:10.1210/mend.14.10.0543 |
Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D'Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. (10 February 1999). Opposing Actions of Intact and N-Terminal Fragments of the Human Prolactin/Growth Hormone Family Members on Angiogenesis: An Efficient Mechanism for the Regulation of Angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 96 (4), 1246-51. doi:10.1073/pnas.96.4.1246 |
Lee, H., Struman, I., Clapp, C., Martial, J., & Weiner, R. I. (1998). Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology, 139 (9), 3696-703. doi:10.1210/endo.139.9.6194 |
D'Angelo, G., Struman, I., Martial, J., & Weiner, R. I. (1995). Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proceedings of the National Academy of Sciences of the United States of America, 92 (14), 6374-8. doi:10.1073/pnas.92.14.6374 |
Goffin, V., Struman, I., Mainfroid, V., Kinet, S., & Martial, J. (23 December 1994). Evidence for a Second Receptor Binding Site on Human Prolactin. Journal of Biological Chemistry, 269 (51), 32598-606. |
Goffin, V., Struman, I., Goormaghtigh, E., & Martial, J. (01 June 1993). The Addition of Nine Residues at the C-Terminus of Human Prolactin Drastically Alters Its Biological Properties. European Journal of Biochemistry, 214 (2), 483-90. doi:10.1111/j.1432-1033.1993.tb17945.x |